Filing Details

Accession Number:
0001209191-22-020984
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-03-24 19:24:04
Reporting Period:
2022-03-22
Accepted Time:
2022-03-24 19:24:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1628171 Revolution Medicines Inc. RVMD Biological Products, (No Disgnostic Substances) (2836) 472029180
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1776412 Thilo Schroeder C/O Revolution Medicines, Inc.
700 Saginaw Drive
Redwood City CA 94063
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-03-22 5,440 $22.15 701,666 No 4 P Indirect By Nextech Crossover I SCSP
Common Stock Acquisiton 2022-03-22 71,186 $23.18 772,852 No 4 P Indirect By Nextech Crossover I SCSP
Common Stock Acquisiton 2022-03-22 53,501 $23.69 826,353 No 4 P Indirect By Nextech Crossover I SCSP
Common Stock Acquisiton 2022-03-23 37,708 $23.61 864,061 No 4 P Indirect By Nextech Crossover I SCSP
Common Stock Acquisiton 2022-03-23 15,410 $23.99 879,471 No 4 P Indirect By Nextech Crossover I SCSP
Common Stock Acquisiton 2022-03-24 49,119 $24.26 928,590 No 4 P Indirect By Nextech Crossover I SCSP
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Nextech Crossover I SCSP
No 4 P Indirect By Nextech Crossover I SCSP
No 4 P Indirect By Nextech Crossover I SCSP
No 4 P Indirect By Nextech Crossover I SCSP
No 4 P Indirect By Nextech Crossover I SCSP
No 4 P Indirect By Nextech Crossover I SCSP
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 2,668,214 Indirect By Nextech V Oncology S.C.S., SICAV-SIF
Common Stock 300,000 Indirect By Nextech VI Oncology SCSp
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.49 to $22.47 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  2. Nextech Invest AG is the investment advisor of Nextech Crossover I SCSP ("Nextech Crossover"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech Crossover. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
  3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.50 to $23.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.50 to $23.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  5. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.88 to $23.87 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  6. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.88 to $24.20 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  7. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.85 to $24.68 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  8. Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF ("Nextech V"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech V. The reporting person disclaims beneficial ownership of such shares,except to the extent of any pecuniary interest therein.
  9. Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares,except to the extent of any pecuniary interest therein.